Feedback
Settings

Settings

Goto Application

11,570 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(DWRXFEITVBNRMK-JXOAFFINSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 1,157
1.WO/2026/022136ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF METABOLIC DISORDERS
WO - 29.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/EP2025/070967 Applicant PROQR THERAPEUTICS II B.V. Inventor KLEIN, Bart
The present invention relates to antisense oligonucleotides (AONs) that can mediate RNA editing by binding to a target RNA nucleic acid molecule in a cell and recruiting an endogenous deaminating enzyme in the cell to deaminate a target adenosine in the target RNA molecule to an inosine. The target RNA molecule is a transcript molecule from the pro-opiomelanocortin (POMC) gene encoding the β-MSH peptide. Preferably, the RNA editing changes a tyrosine to a cysteine at position 221 (Y221C) in the POMC prohormone, which results in a loss-of-function of the encoded β-MSH peptide. In turn, treatment using the AONs as disclosed will result in gain of body weight and increased BMI, thereby lowering the risk of suffering from weight loss related metabolic disorders such as cachexia.
2.WO/2026/025031MRNA ENCODING MAGEB2 TCER MOLECULE
WO - 29.01.2026
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
 Appl.No PCT/US2025/039258 Applicant MODERNATX, INC. Inventor CAROLAN, James
Present disclosure provides engineered polynucleotides encoding MAGEB2 binding proteins, including MAGEB2-specific TCER® polypeptides capable of promoting immune targeting of cancer cells expressing MAGEB2. The disclosure also provides pharmaceutical compositions and kits comprising the same, and methods of use and treatment of MAGEB2-positive cancers.
3.WO/2026/023682NON-NATURAL POLYNUCLEOTIDE
WO - 29.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/JP2025/026385 Applicant DAIICHI SANKYO COMPANY, LIMITED Inventor IMAI, Sunao
The present invention provides, for example, a non-natural polynucleotide being a single-stranded polynucleotide or a complementary strand thereof, the single-stranded polynucleotide comprising (a) a guide strand for a target nucleic acid molecule, (b) a passenger strand, and (c) a combination of a 5'-flanking region, a loop region, and a 3'-flanking region. The combination of the 5'-flanking region, the loop region, and the 3'-flanking region is any one combination selected from the group consisting of (i) to (xi) described in the present description, wherein: the passenger strand is disposed between the 5'-flanking region and the loop region, and the guide strand is disposed between the 3'-flanking region and the loop region; or the guide strand is disposed between the 5'-flanking region and the loop region, and the passenger strand is disposed between the 3'-flanking region and the loop region.
4.WO/2026/025099COMPOSITIONS AND METHODS FOR INHIBITING DNMT1 METHYLATION ACTIVITY FOR REDUCING CHEMOTHERAPY INDUCED AMPLIFICATION AND REARRANGEMENT IN MIXED LINEAGE LEUKEMIA (MLL)
WO - 29.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/039448 Applicant INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER Inventor WHETSTINE, Johnathan, R.
Compositions and methods for control of DNMT1-mediated site-specific copy gains and genomic insertions associated with mixed lineage leukemia are provided.
5.WO/2026/021698NUCLEIC ACID PARTICLE
WO - 29.01.2026
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
 Appl.No PCT/EP2025/061696 Applicant BIONTECH SE Inventor KAISER, Andrew
The present invention generally relates to nucleic acid particles, in particular nucleic acid-lipid particles, comprising targeting moieties that are bound to the particles, and to pharmaceutical compositions containing the nucleic acid particles and their uses in medicine.
6.WO/2026/018181IMMUNOGENIC COMPOSITIONS AND USES THEREOF
WO - 22.01.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2025/057203 Applicant PFIZER INC. Inventor HUANG, Bridget Yih Jiin
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
7.WO/2026/019998VACCINES FOR KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS
WO - 22.01.2026
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2025/038046 Applicant THE CLEVELAND CLINIC FOUNDATION Inventor JUNG, Jae
Provided herein are compositions, systems, kits, and methods for immunizing a subject against Kaposi's sarcoma-associated herpesvirus (KSHV) with a composition: i) comprising a plurality of nanoparticles self-assembled from a plurality of fusion proteins that comprise: a) at least a portion of a Ferritin protein, and b) an immunogenic protein comprising at least a portion of: KSHV K8.1 protein, or ii) polynucleotides encoding said fusion proteins (e.g., human codon optimized mRNA sequences present in lipid nanoparticles). In other embodiments, provided herein are compositions, systems, and kits, and methods for immunizing a subject against KSHV employing a human codon optimized nucleic acid sequence (e.g., mRNA) encoding a KSHV K8.1 protein.
8.WO/2026/015937NOVEL TREATMENT FOR DIABETES AND OBESITY
WO - 22.01.2026
Int.Class A61K 38/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
 Appl.No PCT/AU2025/050761 Applicant THE UNIVERSITY OF MELBOURNE Inventor EKINCI, Elif Ilhan
The present invention relates to compositions for the prevention or treatment of a metabolic disorder. In one aspect, the invention relates to the regulation of blood glucose levels and/or lipid metabolism with a composition of the invention.
9.WO/2026/020002ENHANCING NEURONAL RESISTANCE TO NEURODEGENERATION
WO - 22.01.2026
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
 Appl.No PCT/US2025/038051 Applicant NEW YORK UNIVERSITY Inventor NGUYEN, Hoa, Quang, My
The application relates to methods of enhancing neuronal resistance to disease characterized by TAR DNA-binding protein 43 (TDP-43) mislocalization or dysfunction, e.g., a neurodegenerative disease.
10.WO/2026/017917RNAS WITH REDUCED RIBOSOMAL FRAMESHIFT EXPRESSION PRODUCTS
WO - 22.01.2026
Int.Class A61K 31/7115
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
 Appl.No PCT/EP2025/070923 Applicant ETHRIS GMBH Inventor BEGUIN, Estelle
The present invention relates to RNAs and compositions comprising said RNAs designed for reducing or avoiding ribosomal frameshift mutations. More particularly, the invention pertains to therapeutic compositions that essentially do not exhibit ribosomal frameshift mutation. These compositions include specific carriers and therapeutic agents suitable for various medical applications.
# -